Applications of D-Aspartic Acid 4-Tert-Butyl Ester in Industrial Manufacturing

D-Aspartic Acid 4-Tert-Butyl Ester serves as a specialized intermediate and functional additive within multiple high-value downstream sectors due to its precise chiral configuration and tailored physical properties. As a direct manufacturer, we support global industrial partners with reliable supply and application-specific guidance compliant with international standards for advanced synthesis and formulation.

1. Peptide Synthesis for Pharmaceutical Intermediates

Many pharmaceutical manufacturers rely on this esterified amino acid as a protected D-aspartic acid source to build chiral pharmaceutical building blocks, especially when synthesizing custom peptide-based APIs such as hormone analogs and neuromodulators. The compound supports solid-phase and liquid-phase peptide synthesis, facilitating selective deprotection and efficient coupling steps.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• USP/NF and Ph. Eur. monographs for peptide APIs
• 21 CFR Part 210/211 (FDA cGMP)
• EMA Guideline on the Specification Limits for Residues of Metal Catalysts (EMA/CHMP/SWP/4446/2000)

Typical usage ratio

• 0.5–2.0 molar equivalents per targeted peptide unit; adjustment based on targeted peptide length and resin loading during synthesis

Downstream process integration

• Incorporated at the early coupling step as a protected D-aspartic acid unit on resin or in solution; subsequent deprotection releases the functional D-Asp moiety for sequence extension

Final product types

• Peptide hormone active pharmaceutical ingredients
• Peptidomimetic drug intermediates
• Custom oligopeptide research compounds

2. Chiral Auxiliary in Fine Chemical Synthesis

Chemical manufacturers employ this compound as a chiral auxiliary to improve the stereoselectivity in asymmetric synthesis of certain active intermediates, such as those used in agrochemicals and specialty materials. Its stability and ease of removal help support complex multi-step transformations while maintaining optical purity.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• REACH Regulation (EC 1907/2006) compliance for safe handling and registration
• GLP (Good Laboratory Practice) as applicable in fine chemical R&D

Typical usage ratio

• 5–20 mol% relative to substrate; precise loading optimized according to the target chiral center and auxiliary removal protocol

Downstream process integration

• Utilized at the asymmetric induction stage, linked temporarily to synthons to enable stereoselective reactions, followed by cleavage and recovery of chiral auxiliary

Final product types

• Optically active agrochemical intermediates
• Specialty plasticizer precursors
• Fluorinated fine chemical compounds

3. Active Ingredient for Research Reagents

Biotechnology and analytical reagent companies incorporate this ester as a core structure for preparing custom research reagents, including substrate analogs for enzymology studies and ligand libraries for receptor screening. Laboratory-scale and pilot batch production focus on precise incorporation with analytical traceability under controlled release or activation schemes.

Industry compliance standards

• ISO 13485:2016 (for in vitro diagnostic and lab reagents)
• OECD GLP principles
• International Air Transport Association (IATA) regulations for reagent shipping

Typical usage ratio

• 0.1–2.0% weight/weight; depends on the complexity of target reagents and labeling density in the final composition

Downstream process integration

• Introduced at the building block insertion or functional group modification stage, either as a core moiety for ligand generation or as an active control substrate

Final product types

• Custom enzyme substrate kits
• Affinity chromatography ligands
• Small-molecule screening libraries

4. Precursor for Non-Natural Amino Acid Derivatives

This molecule finds application in the synthesis of non-proteinogenic amino acid derivatives used in advanced biotech materials. Manufactured under controlled conditions, downstream processors convert the protected ester to D-aspartic acid analogs for incorporation into novel therapeutic carriers or performance materials.

Industry compliance standards

• ISO 9001:2015 process controls
• Relevant local chemical safety regulations (e.g., OSHA for the US, China GB/T 16483-2008 MSDS guidelines)
• COA requirements specified by end-user quality control

Typical usage ratio

• Varies from 0.05–0.5 molar ratio depending on the complexity and length of the synthetic sequence

Downstream process integration

• Acts as the first protected amino acid moiety introduced in the assembly of side-chain modified analogs; protection group removed after chain extension for activation to the free acid or further derivatization

Final product types

• Functionalized polyamino acid carriers
• Peptide-based material additives
• Non-natural amino acid feedstocks for conjugation